Background: Children with ISS have an array of causes that lead to short stature and/or poor growth velocity. Genetic causes of short stature, notably SHOX mutations, can be associated with subtle skeletal disproportion with shorter limbs, manifesting as increased sitting-to-standing height ratios or SDS.
Objective and hypothesis: Children with ISS and skeletal disproportions have a diminished growth response to GH treatment compared to children with proportionate short stature after 1 year (short-term) and at near-adult height (NAH; long-term).
Method: ISS patients registered in Pfizer international growth database with a stimulated peak GH >10 μg/l and treated with GH were included. Short- and long-term growth responses were analyzed. Sitting height % SDS was grouped as: normal (SDS −1.0<1.1), mild (SDS 1.1<2.1), and moderate (SDS >2.1) disproportionate short stature. Wilcoxon rank sum test was used for univariate statistical comparisons. ANOVA was used for group comparisons. P-value <0.05 was considered significant.
Results: Prior to GH treatment, the ISS group displayed Gaussian distribution for skeletal proportion. For short-term analyses, the number of patients in each group was: normal (n=193), mild (n=191), and moderate (n=140). The corresponding number of patients in each group attaining NAH was: normal (57), mild (52), and moderate (28). Short-term growth responses, expressed as Studentized Residuals using the KIGS ISS 1st-year prediction model (Ranke MB et al. Horm Res 2007; 68:5362), showed a trend toward poorer growth response with greater severity of disproportion (mean values; normal=−0.04, mild=−0.16, and moderate=−0.25, P=0.07). Long-term growth showed a larger difference, expressed as delta height SDS from GH start to NAH (median values; normal/mild=1.75 vs moderate=1.39, P<0.05)
Conclusion: Children with ISS and skeletal disproportion (shorter limbs) have reduced long-term height responsiveness to GH compared to those without disproportion suggesting subtle GH resistance in the former.
Conflict of interest: C Camacho-Hubner and A Lindberg are employees of Pfizer Inc. W Cutfield is a member of the KIGS Steering Committee.
Funding: Pfizer International Growth Database (KIGS) currently is a static database sponsor by Pfizer Inc. No authors were paid to conduct the research study submitted in this abstract.
01 - 03 Oct 2015
European Society for Paediatric Endocrinology